Landscape Capital Management L.L.C. Purchases Shares of 442,196 IO Biotech, Inc. (NASDAQ:IOBT)

Landscape Capital Management L.L.C. purchased a new stake in shares of IO Biotech, Inc. (NASDAQ:IOBT) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 442,196 shares of the company’s stock, valued at approximately $407,000. Landscape Capital Management L.L.C. owned about 0.67% of IO Biotech as of its most recent filing with the Securities & Exchange Commission.

Separately, Vontobel Holding Ltd. bought a new position in IO Biotech during the 4th quarter worth $30,000. 54.76% of the stock is currently owned by institutional investors and hedge funds.

IO Biotech Stock Down 7.5 %

IOBT stock opened at $0.91 on Tuesday. The firm has a market cap of $59.95 million, a price-to-earnings ratio of -0.66 and a beta of 0.08. The company’s fifty day simple moving average is $0.97 and its 200 day simple moving average is $0.97. IO Biotech, Inc. has a 12-month low of $0.66 and a 12-month high of $1.79.

Analyst Upgrades and Downgrades

A number of research firms have commented on IOBT. Piper Sandler upgraded IO Biotech to a “strong-buy” rating in a research report on Wednesday, March 12th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of IO Biotech in a research note on Tuesday, April 1st.

IO Biotech Profile

IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.